ClinicalTrials.gg
CompletedNCT03972462Updated Mar 6, 2020

NPC-12G Gel 0.2% Sirolimus PK Bridging Study

A Phase 1 interventional study of NPC-12G Gel 0.2% and Rapamune® 2 mg tablet in Bioavailability Study, sponsored by Nobelpharma. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-06.

Sponsored by Nobelpharma · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2019, 7 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is designed to describe the relative systemic bioavailability of topical and oral sirolimus formulations.

02

Conditions studied

  • Bioavailability Study
03

In context

Lead sponsor

Nobelpharma is the lead sponsor of 34 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, non-smoker (no use within 3 months prior to screening), ≥ 18 and ≤ 65 years of age, with > 18.5 and \< 30.0 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females
  • Females of who are sexually active with a male partner must be willing to use one of acceptable method throughout the study and for 12 weeks after the last study drug administration

Exclusion criteria

Exclusion Criteria

  • Any sign of eczema/dermatitis, skin lesion, wound, or infection at the application site, or any other conditions that would prevent a safe application of the gel formulation.
  • Laser or surgery at the gel application site within 2 weeks before the gel application.
  • Positive alcohol breath test, urine drug screen or urine cotinine test at screeningation
  • History of allergic reactions or to sirolimus, sirolimus derivatives, or of NPC-12G Gel
  • Use of any drugs known to induce or inhibit metabolism within 30 days prior to the first study drug administration
  • Positive pregnancy test at screening
  • Breast-feeding subject
  • History of active tuberculosis or exposure to endemic areas within 8 weeks prior to QuantiFERON®-TB testing performed at screening
  • Positive QuantiFERON®-TB test with positive chest X-ray, indicating possible tuberculosis infection
  • Immunization with a within 1 month prior to dosing or planned vaccination during the study and up to 3 weeks after the last study drug administration
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    NPC-12G Gel 0.2% (Period 1)

    A single 800 mg quantity weight (1.6 mg sirolimus) dose will be applied to the central face on Day 1.

    Drug: NPC-12G Gel 0.2%

  • Active comparator
    Rapamune Tablet (Period 2)

    Rapamune® (sirolimus) 2 mg tablet for oral dosing.

    Drug: Rapamune® 2 mg tablet

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-48

    Time frame: Sampling: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours post-dose

  2. Cmax

    Time frame: Sampling: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours post-dose

  3. Tmax

    Time frame: Sampling: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours post-dose

07

Study locations

1 site
  • InVentiv Health Clinical Research Services LLC
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Jun 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2019
First posted
Jun 3, 2019
StartActual
May 31, 2019
Primary completionActual
Jun 17, 2019
CompletionActual
Jun 17, 2019
Last update
Mar 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03972462
Lead sponsor
Nobelpharma
Responsible party
Sponsor
First posted
Jun 3, 2019
Start date
May 31, 2019
Primary completion
Jun 17, 2019
Completion
Jun 17, 2019
Last update
Mar 6, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sirolimus · Topical Sirolimus

Start the discussion